AIM ImmunoTech Inc. Gibt Update zum Ampligen Long COVID Entwicklungsprogramm -Am 18. Mai 2022 um 14:00 Uhr | MarketScreener
AIM ImmunoTech receives regulatory go-ahead for Phase 2 trial of investigational drug Ampligen for patients with post-COVID conditions | NYSE:AIM
AIM ImmunoTech on X: "AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. https://t.co/Qsw4vpA0Ok $AIM #
AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions
![Net Present Value Model: AIM ImmunoTech Inc's Ampligen - Market Research Reports & Consulting | GlobalData UK Ltd. Net Present Value Model: AIM ImmunoTech Inc's Ampligen - Market Research Reports & Consulting | GlobalData UK Ltd.](https://www.globaldata.com/store/wp-content/uploads/sites/2/2023/07/reportcover-LG5.webp)